About: Prostate Cancer Radiotherapy Recommendations in Response to COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Prostate Cancer Radiotherapy Recommendations in Response to COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
title	Prostate Cancer Radiotherapy Recommendations in Response to COVID-19
Creator	Jackson, William Chen, Chen, Ronald Choudhury, Ananya Dess, Robert Henry, Ann Kishan, Amar Mahal, Brandon Mcbride, Sean Mitin, Timur Spratt, Daniel Spratt, E Syndikus, Isabel Tree, Alison Yu, James Zaorsky, Nicholas
source	Elsevier; Medline; PMC; WHO
abstract	PURPOSE: During a global pandemic the benefit of routine visits and treatment of cancer patients must be weighed against the risks to patients, staff, and society. Prostate cancer is one of the most common cancers Radiation Oncology departments treat, and efficient resource utilization is essential in the setting of a pandemic. Herein, we aim to establish recommendations and a framework by which to evaluate prostate radiotherapy management decisions. PATIENTS AND METHODS: Radiation Oncologists from the United States and United Kingdom rapidly conducted a systematic review and agreed upon recommendations to safely manage prostate cancer patients during the COVID-19 pandemic. A RADS framework was created: Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy was applied to determine appropriate approaches. RESULTS: Recommendations are provided by National Comprehensive Cancer Network (NCCN) risk group, including clinical node positive, post-prostatectomy, oligometastatic, and low volume M1 disease. Across all prostate cancer stages, telemedicine consultations and return visits were recommended when resources/staff available. Delays in consultations and return visits was deemed safe based on stage of disease between 1-6 months. Treatment can be avoided or delayed until safe for very low, low, and favorable intermediate-risk disease. Unfavorable intermediate-risk, high-risk, clinical node positive, recurrence post-surgery, oligometastatic, and low-volume M1 disease can receive neoadjuvant hormone therapy for 4-6 months as necessary. Ultrahypofractionation was preferred for localized, oligometastatic, and low volume M1, and moderate hypofractionation was preferred for post-prostatectomy and clinical node positive disease. Salvage was preferred to adjuvant radiation. CONCLUSION: Resources can be reduced for all identified stages of prostate cancer. The RADS (Remote visits, and Avoidance, Deferment, and Shortening of radiotherapy) framework can be applied to other disease sites to help with decision making in a global pandemic.
has issue date	2020-04-01(xsd:dateTime)
bibo:doi	10.1016/j.adro.2020.03.010
bibo:pmid	32292839
has license	no-cc
sha1sum (hex)	8f543f0b9f240c1a5be36650c73b476e14ebae5e
schema:url	https://doi.org/10.1016/j.adro.2020.03.010
resource representing a document's title	Prostate Cancer Radiotherapy Recommendations in Response to COVID-19
has PubMed Central identifier	PMC7118610
has PubMed identifier	32292839
schema:publication	Adv Radiat Oncol
resource representing a document's body	covid:8f543f0b9f240c1a5be36650c73b476e14ebae5e#body_text
is schema:about of	named entity 'COVID-19' named entity 'CANCER RADIOTHERAPY' named entity 'TITLE' named entity 'RECOMMENDATIONS' named entity 'PRE' named entity 'JOURNAL ' named entity 'COVID-19' named entity 'PROSTATE CANCER' named entity 'PROOF' named entity 'RESPONSE TO' named entity 'Radiotherapy' named entity 'Prostate Cancer' named entity 'morbidity' named entity 'risks and benefits' named entity 'prostate cancer' named entity 'fiducial markers' named entity 'iatrogenic' named entity 'heterogeneous disease' named entity 'radiation oncology' named entity 'prostate cancer' named entity 'radiotherapy' named entity 'fiducial markers' named entity 'PSA' named entity 'systematic reviews' named entity 'COVID-19 global pandemic' named entity 'COVID-19 pandemic' named entity 'NCCN' named entity 'radiation therapy' named entity 'radiation oncology' named entity 'fiducial markers' named entity 'morbidity' named entity 'MRI' named entity 'neoadjuvant' named entity 'radiotherapy' named entity 'radiotherapy' named entity 'radiotherapy' named entity 'COVID-19' named entity 'ASCO' named entity 'PSA' named entity 'Prostate cancer' named entity 'Cancer treatment' named entity 'Radiation Oncology' named entity 'exigent circumstances' named entity 'older age' named entity 'infection' named entity 'anesthesia' named entity 'hypofractionation' named entity 'radiotherapy' named entity 'prostate cancer' named entity 'localized prostate cancer' named entity 'treatment of cancer' named entity 'brachytherapy' named entity 'radiotherapy' named entity 'clinical trials' named entity 'radiotherapy' named entity 'localized prostate cancer' named entity 'analgesics' named entity 'morbidity' named entity 'comorbidities' named entity 'image guidance' named entity 'fractionation' named entity 'fractionation' named entity 'watchful waiting' named entity 'local anesthesia' named entity 'brachytherapy' named entity 'randomized trials'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2025 OpenLink Software